WUMC-Cancer and Leukemia Group B

WUMC-癌症和白血病 B 组

• 批准号: 6887426
• 负责人: NANCY L BARTLETT
• 金额: $ 32.71万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-08 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6887426
• 关键词: aging; antineoplastics; breast neoplasms; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trial phase I; clinical trial phase II; clinical trial phase III; combination cancer therapy; combination chemotherapy; cooperative study; doxorubicin; drug resistance; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human subject; human therapy evaluation; irinotecan; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pathology; patient oriented research; prostate neoplasms; psychological aspect of cancer; quality of life; respiratory neoplasm; tamoxifen; thorax neoplasm; urinary tract neoplasms

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin's lymphoma, Hodgkin's lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials.

描述（改编自申请人摘要）：华盛顿大学自1986年以来一直是CALGB的主要成员机构。在过去的五年中，华盛顿大学医学中心（WUMC）的癌症研究项目经历了巨大的增长。巴恩斯犹太医院是圣路易斯最大的医院，每年诊断出5400多名癌症患者，并且仍然是密苏里州东南部和伊利诺伊州南部的主要转诊中心。WUMC的Siteman癌症中心（SCC）于2001年8月获得nci指定的癌症中心地位。SCC为成功竞争NCI癌症中心支持基金而开发的基础设施大大提高了我们开展临床癌症研究的各个方面的能力，包括合作小组试验。我们最近扩大机构研究的努力将显著增强我们在下一个拨款周期向CALGB贡献概念的能力，特别是在血液恶性肿瘤、胸部肿瘤学和药物基因组学领域。1998年至2002年间，16名华盛顿大学的医生和研究助理在36个不同的CALGB科学和行政委员会任职。WUMC研究人员主持了12项CALGB研究，包括非霍奇金淋巴瘤、霍奇金淋巴瘤、前列腺癌、间皮瘤的II期研究，以及一些药代动力学和药物基因组学相关科学研究。另外六项研究正处于最后发展阶段。在此拨款期间，CALGB试验的应计费用继续增加，从1998年到2001年，每年平均有183名患者注册参加治疗性和非治疗性试验。应计治疗试验从1998年的61例增加到2001年的105例。根据迄今为止的注册情况，2002年CALGB试验的预计应计数估计为312项，其中治疗性研究为136项。下一个拨款周期的计划包括：1)所有当前WUMC研究人员继续参与；2)增加I期研究人员的参与，以促进CALGB内II期研究的发展；3)至少另外5名WUMC研究人员参与CALGB活动，包括对GU肿瘤学、生活质量、干细胞移植和白血病、白血病相关科学和放射肿瘤学感兴趣的教员；5)继续努力增加应计收益。特别是少数应计项目，CALGB试验。